NCT01763164 2021-03-22
Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma
Pfizer
Phase 3 Completed
Pfizer
The Clatterbridge Cancer Centre NHS Foundation Trust
University of Pittsburgh
Vical
University of Turku
Facet Biotech